To develop, commercialize and capture significant market share with the Company's breakthrough photometric instruments and proprietary nanostructure reagents in large scale global markets including food safety, public health, environmental monitoring, process control, medical diagnosis, and other chemical and biological opportunities.


Optokey, Inc. is an innovator of photometric test solutions based in the San Francisco Bay Area, California. Optokey was founded in 2009 by a team of scientific researchers from the University of California at Berkeley and the Lawrence Berkeley National Laboratory. The Company's solutions are based on world-class technology patented through the Lawrence Berkeley National Labs. Optokey's unique line of photometric assays, including advanced instrumentation and proprietary reagents, are tailored for a wide range of global high-volume applications. The Company is privately held.

The new Optokey photometric technology offers proven breakthrough performance expertly engineered into fast, low-cost test systems for analytical chemistry and biochemistry. The system identifies and quantifies elements out of complex mixtures based on their idiosyncratic molecular characteristics. The sophisticated software enables fast and accurate results on a routine basis.

Optokey is focused on providing its best-in-class analytical solutions to specific global issues where this unique technology becomes the standard or benchmark, and where these applications yield improvements in overall environmental quality, conservation, general health and safety for all.


The Optokey founders include scientists and engineers from University of California at Berkeley, Lawrence Berkeley National Laboratories (LBL), Lawrence Livermore National Laboratory, University of California at San Francisco, University of Illinois at Urbana-Champaign, and Silicon Valley. The team members are recognized experts in optical microscopy and spectroscopy in both instrumentation and applications in chemical, biological, and biomedical environments.

The team has extensive expertise in product and process development, commercialization of new hardware, development and commercialization of software and chemistry covering a wide array of technologies in areas of anatomy, physiology, chemicals and drugs as well as medical diagnostics.

The team has successfully and decisively demonstrated near perfect performance of the new technology in international double-blinded testing competition against current standard methods.

The LBL group has been working for years on closely associated nanotechnology, biochemistry, and a broad array of interrelated research interests. These scientists have combined novel optical and laser technologies with breakthroughs in nanostructure reagents to open the door to these previously unobtainable results.


Fanqing Frank Chen
Dr. Fanqing Frank Chen has been founder for several successful companies, including Optokey, Inc., a nanophotonics company focusing on miniaturized high data content measurement technology for chemical analysis and healthcare. He is an expert in the field of life sciences, chemistry, material sciences, and nanotechnology. He specializes in helping clients in these industries through R&D collaborations, or helping to identify partner companies for M&A and corporate equity investments.

Dr. Chen has been a Staff Scientist at prestigious Lawrence Berkeley National Laboratory. With more than 20 years of experience in research and technology development in world leading research institutes such as Chinese Academy of Science-Shanghai Institute of Biological Sciences (SIBS), Los Alamos National Laboratory, Picower Institute for Medical Research (acquired by Feinstein Institute for Medical Research), New York University-Mount Sinai Hospital, more than a decade at Lawrence Berkeley National Laboratory since year 2000, and more than 20 years of experience in business management and consulting, his diverse global client base includes startups, established companies, Fortune 100 companies in the U.S., Europe, and Asia. His effort and encompasses a wide variety of material sciences, chemistry, health, biotechnology, and nanotechnology-related areas, including microfluidics, nanoscale measurements, drug discovery, instrumentation miniaturization, medical devices, diagnostics, bioremediation, nanotechnology, chemistry, and environment monitoring.

Dr. Chen joined NewCap Partners (a private investment banker, member FINRA/SIPC) as Consultant, and as Nanotechnology Advisory in 2008-2012. He also was also partner in Muse Asset Management from 2009-2012. Frank served as QB3 China Representative in 2007 for its commercial business development activity in China.

Frank's areas of business expertise include: strategic alliance formation, business development, competitive intelligence and strategic planning, organizational development, technology assessment and licensing, intellectual property development, project management, product development, and manufacturing. During the last 15 years, his efforts have focused on formation of alliances with companies in U.S., Europe and China. His advisory services focus on assisting small and medium-sized, fast growing companies in the informatics, instrumentation, miniaturization, material sciences, nanotechnology arenas.

Dr. Chen's researches were funded by NIH, DOD, DARPA, NASA and Agilent Foundation. He has been on Editorial Board Member of multiple scientific journals, and constantly serves as reviewers for top tier journals such as Nature Nanotechnology, Nature Material, JACS, etc. He was Professor of Nanotechnology (2008-2011) at Zhejiang-California Nanosystems Institute, Zhejiang University, where he was the founding Director for its International Nanobiotechnology Center. He is Adjunct Professor of Chemistry at Fudan University Chemistry Department, Adjunct Professor of Biology at Fudan University Life Sciences College. His other associations included Lawrence Livermore National Laboratory (Guest Scientist), Children's Hospital of Oakland Research Institute (CHORI, Guest Scientist).

Dr. Chen has a Ph.D. from Graduate Program of Los Alamos National Laboratory, and a B.S. in Biochemistry from Fudan University. He has more than 50 peer-reviewed publications such as Nature Nanotechnology, PNAS, and ACSNano, and more than 30 patents, more than 50 invited speeches. He is fluent in Mandarin and English.

Robert Chebi

VP, Foundry Manufacturing

Prof. Richard Mathies - Co Founder
Fanqing Frank Chen
Robert Chebi
Jason Wang
Tiziana Bond

Robert Chebi
Robert brings to Optokey 25 years of experience in semiconductor manufacturing. Robert is a seasoned Technologist and Executive Leader with over 20 years of experience in the most dynamic sector of the Global Hi-Tech Chip Industry - at Semiconductor Integrated Device Manufacturers, and at Capital Equipment Manufacturers. He is accomplished in leading, motivating, and building diverse and cross-functional global organizations focusing on Product Development, Process Characterization, and Productivity Enhancements. Robert has travelled globally interacting with customers, marketing and promoting technical products and solutions, developing business opportunities, and increasing market share. Robert is a visionary leader and pragmatic thinker with 18 patents issued and pending.

After his graduate education in Chemical Engineering, Robert started his career at Digital Equipment Corporation (DEC) as a Technologist in Thin Films Development and Advanced Process Integration. In 1988, Robert was selected as one of 5 distinguished Technologists, representing DEC, to start-up Sematech, a joint consortium of U.S. Microelectronic Companies and the U.S. Government, to re-establish U.S. superiority and competitiveness in Semiconductor Technology.

In 1991, Robert joined the Advanced Products Research and Development Laboratory (APRDL), in Motorola, as a Thin Films and Etch Technologist, where he was tasked with the development of new processes and an advanced critical dielectric etcher in a Joint Development Program with Applied Materials.

In 1993, Robert Joined Lam Research, where he held various Product Development and Executive Leadership Positions - for the next 15 years, excelling in strategic planning and tactical execution. Robert had responsibilities in Conductor and Dielectric Etch Business Units, and led the Advanced Critical Post-Implant Strip & Clean, and 3DIC/TSV Deep Silicon Etch organizations. His job functions focused on Product, Business, and Market Share Development, where revenue and customer satisfaction were key corporate measures.

In 2009, Robert joined Applied Materials as Director of Technology -200mm Products and Solutions Group. He managed a global cross-functional organization of Technologists in China, Singapore, and Europe, focusing on Applications and Product Development for emerging markets (i.e. Power Devices/MEMS/3DIC-TSV) spanning across Etch, Thin Films (i.e. CVD, PVD, and Epi), and CMP. He directed all phases of Product Development for a new advanced deep Silicon etcher.

Jason Wang
Dr. Wang is an expert in integrated automation technology on R&D and productions. Having over 25 years of experience, Jason has held a variety of advisor, VP level management, and technical positions in Areesys Corp, Enovix Corp, Freeslate Inc., Movo Technology Co. Ltd, and Symyx Technologies; he also has research experience at Los Alamos National Laboratory, Canadian TRIUMF National Lab, and Stanford Linear Accelerator Center. Jason has extensive knowledge in high throughput technology with multiple technical inventions. Recently, he's directed his focus to business opportunities across the Pacific Ocean. By building a brand new, multi-million dollar market, Jason has successfully established some of the largest research projects in alliance with the several of the top tier Asian companies.

Jason was the chairman and president in 2009-2010 for the Chinese American Semiconductor Professional Association (CASPA), one of the largest non-profit professional association in US., with thousands individual members and 70+ corporation members including Broadcom, TSMC, Intel, Applied Materials, Huawei, Global Foundry etc. He is currently serving as one of advisory board member in CASPA.

Jason received a Bachelor's degree in Physics in Peking University, a Master's degree in Physics and Computer Engineering, and a PhD in Physics from Syracuse University.

Tiziana Bond
Dr. Tiziana C. Bond is senior engineer and capability leader in Engineering at Lawrence Livermore National Laboratory. She has been leading the development of integrated photonic platforms for all optical encryption circuits, miniature laser-based tunable integrated gas sensors, label-free chem-bio detectors, and radiation diagnostic systems. Her current interests are in nanotechnology, plasmonics, surface enhanced Raman and IR sensors, enhanced photovoltaics, energy harvesting and novel nanolaser architectures. She has more than 50 papers published in international journals and conference proceedings and holds 8 patents.She has led multiple multi-million dollar projects throughout her career and has extensive experience developing compact integrated sensors. Lately she has also been supporting LLNL new program LIFE (Laser Inertial Energy Fusion), ad NIF (National Ignition Facility) in laser&optics design& operations. She sits in various internal and external committee, including the User Executive Committee at the Molecular Foundry at LBNL and outreach programs (Tri-Valley Science Fair).

She received the Laurea degree (cum laude) and Ph.D. degree, both in EE, from the Polytechnic of Bari, Italy. Prior to joining LLNL, she held two postdoctoral positions, at the University of Florida and the Georgia Institute of Technology.

Richard A. Mathies
He received his B. S. Degree in Chemistry in 1968 at the University of Washington working with Martin Gouterman. He earned the M. S. Degree in 1970 and the Ph. D. in 1973 in Physical Chemistry at Cornell University from Andreas Albrecht. Following two years of postdoctoral study as a Helen Hay Whitney Postdoctoral Fellow at Yale University with Lubert Stryer, he moved to the Chemistry Department at the University of California at Berkeley in 1976 where he is G. N. Lewis Professor of Chemistry and Dean of the College of Chemistry.

Mathies' biophysical research is focused on the use of resonance Raman and time resolved optical spectroscopy to elucidate the structure and reaction dynamics of energy and information transducing photoactive proteins. His extensive work on the photochemistry of the visual pigment rhodopsin has established the structure of the primary photoproduct using time-resolved vibrational spectroscopy, demonstrated that the primary cis-to-trans photoisomerization in vision is complete in only 200 fs, and analyzed the nonstationary state or wavepacket evolution that defines the excited state isomerization mechanism. His recent development of femtosecond stimulated Raman spectroscopy provides a revolutionary new way to study the structural dynamics of photochemical and photophysical processes with complete high resolution Raman vibrational spectra and <50 fs time resolution.

Mathies' work in the area of biotechnology and the Human Genome Project led to the development of new high-speed, high-throughput DNA analysis technologies such as capillary array electrophoresis and energy transfer (ET) fluorescent dye labels for DNA sequencing and analysis. In particular, his development of ET fluorescent labels was a critical contribution to the early completion of the Human Genome sequence. He also pioneered the development of microfabricated capillary electrophoresis devices and microfabricated integrated sample preparation and detection methods for lab-on-a-chip analysis systems that are being applied to DNA sequencing, diagnostics, forensics, pathogen detection and space exploration.

Mathies is author of more than 430 publications and 40 patents on biophysical chemistry, photochemistry, photobiology, bioanalytical chemistry and genome analysis technology. He has also been active in consulting and working with biotechnology companies including Affymax, Affymetrix, Molecular Dynamics, US Biochemical, Amersham-Pharmacia, Bio-Rad, Singulex, and IntegenX among others.